Phaseline

Targets › ZN

ZN: drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 3; Metabolic and endocrine, Infectious disease, Hematology; next expected readout Jul 2027.

Open in Phaseline: the race on ZN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Maryland, BaltimoreZinc Gluconate 30 MG
Zinc supplementation to improve glucose homeostasis
ZNPhase 4Prediabetic StateJul 2028
Harvard School of Public Health (HSPH)Zinc Supplements (dispersible zinc citrate tablets)
Elemental zinc supplementation
ZNPhase 3Neonatal InfectionOct 2027
University of California, San FranciscoZinc gluconate 25 mg/day
Zinc supplementation
ZNPhase 2Sickle Cell DiseaseJul 2027

Conditions

Sickle Cell Disease (2) Prediabetic State (1) Neonatal Infection (1)

Modalities

small molecule (2)

Companies

University of Maryland, Baltimore (1) Harvard School of Public Health (HSPH) (1) University of California, San Francisco (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.